Barry Steinman practices in the area of corporate law. Mr. Steinman represents public and private issuers, underwriters and individual investors in a wide range of transactional work. His experience includes follow-on public offerings of equity, debt and other securities; compliance under federal securities and Blue Sky laws; the fulfillment of ongoing obligations under the SEC's periodic reporting system; preparing proxy statements; effecting resales of securities in the public trading markets under SEC Rule 144; private issuances under SEC sections 4(a)(2), 4(a)(6), 4(a)(7) and Regulation D; and advising boards of directors concerning compliance under securities laws. He has represented clients in public and private mergers and acquisitions transactions as well as advised acquirers and targets, special committees, audit committees and boards of directors in complex negotiated and contested situations, including negotiated mergers, cross-border transactions, strategic alliances, joint ventures, spin-offs, dispositions, tender offers, public to private transactions, and corporate governance issues.
Mr. Steinman is a 2007 graduate of Cornell Law School and a graduate of Concordia University.
Areas of Practice
- Corporate Law
- Securities Law
- Private Equity
- Mergers and Acquisitions
- Represented Unilife Corp. (NASDAQ: UNIS/ASX: UNS), a developer, manufacturer, and supplier of injectable drug delivery systems, in connection with the sale, through Chapter 11 bankruptcy, of substantially all of its assets to an affiliate of OrbiMed Advisors LLC, a leading investment firm focused on healthcare, and Amgen Inc., (NASDAQ: AMGN), a leading biotechnology company that discovers, develops, manufacturers and delivers human therapeutics for patients with serious illnesses.
- Represented Unilife Corp. (NASDAQ: UNIS/ASX: UNS) in connection with its announced effort to seek strategic alternatives, culminating in a strategic collaboration with Amgen Inc. (NASDAQ: AMGN) for Unilife's wearable injectable drug delivery systems to use with Amgen's biologics and other medicines. The deal provides Unilife with investments of up to $90 million from Amgen and restructures Unilife's existing debt with OrbiMed.
- Represented CTI Group (Holdings) Inc. (OTC: CTIG) in its $22.5 million sale to Enghouse Systems Limited (TSX: ESL) through its wholly-owned subsidiary, New Acquisitions Corporation.
- Represented private equity firm Clarion Capital Partners and its portfolio company Lenox Corporation in Lenox's successful $22.2 million bid in the US Bankruptcy Court for the District of Massachusetts to acquire, in a Section 363 sale, substantially all of the assets of Reed and Barton Corporation, a prominent American silversmith manufacturer.
- Represented Aurigene Discovery Technologies Limited in its collaboration, license and option agreement with Curis, Inc. for immuno-oncology and selected precision oncology targets.
- Represented VEREIT, Inc. (NYSE: VER) (formerly American Realty Capital Properties, Inc.), a NYSE-traded real estate investment trust (REIT), in its $3.2 billion "reverse" merger to acquire American Realty Capital Trust III, Inc., a "non-traded" REIT. The deal is structured as a cash-election merger in which the cash portion of the consideration will be limited to 30% of the aggregate merger consideration. The combined company is expected to rank among the five largest triple net lease REITs in the United States.
- Represented Lehigh Gas Partners LP (NYSE: LGP), a wholesale motor fuel distributor, in connection with its $138 million initial public offering.
- Represented FMC Corp. (NYSE: FMC), a leading global chemicals company, in its multinational acquisition of the assets of Adventus Group, which include patents and intellectual property related to bioremediation technology for chlorinated organic compounds, pesticides and hazardous metals, from two private equity companies. The consideration provided in connection with the acquisition was not disclosed.
- Represented a NYSE MKT-traded company in its agreement to acquire a majority equity interest in a full-service investment bank in exchange for the company’s contribution of its $45 million equity interest in its broker-dealer subsidiary.
- Represented a NYSE MKT-traded company in a debt-exchange transaction.
- Represented Orthovita, Inc., a Nasdaq-traded specialty spine and orthopedic company with a portfolio of orthobiologic and biosurgery products, in its agreement to be acquired by Stryker Corp. for $316 million through an all-cash tender offer followed by a second-step merger.
- Represented a national home renovation company in connection with a shareholder buyout and reorganization.
- Represented two nonprofit organizations in the negotiation of their respective educational products and services contracts.
- Represented a privately held investment firm in its acquisition of a publicly held specialty finance company in an equity exchange.
- New York
- Cornell Law School, J.D., 2007
- Concordia University, B.Comm., 2002
Duane Morris LLP
- Partner, 2018-present
- Associate, 2010-2017
- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.
- Associate, 2007-2009
- Summer Associate, 2006
- Co-author, "SEC Adopts 'Regulation A+' Rules," Duane Morris Alert, April 10, 2015
- Co-author, "SEC Proposes Say-on-Pay and Say-on-Golden-Parachute Rules," Duane Morris Alert, November 5, 2010